
Facebook can’t catch a break at the moment, after being widely criticised for its practices over the security of users’ …

After having been knocked by twice by NICE, Roche has finally received a recommendation for Tecentriq’s second-line use in non-small …

Vas Narasimhan’s first few moves as CEO of Novartis indicate that he is not afraid to take bold risks in …

Some of the biggest news this week concerns companies that are looking to move on parts of their business, but …

Roche’s multiple sclerosis drug, Ocrevus (ocrelizumab), has been a big new growth driver for the company, especially in the US, …

Takeda’s surprise announcement, just last week, that it was weighing up a move for Shire had some analysts sceptical about …

Fred van Goor, Principle Research Fellow at Vertex Pharmaceuticals, discusses his history of work in cystic fibrosis and how the …

Back in 2014, Roche entered into strategic collaboration with Inception Sciences to look into the regenerative medicines space for multiple …

New figures show that hospital admissions related to obesity have doubled over the last four years in the UK, placing …

Eli Lilly and Sigilon Therapeutics have announced a partnership that looks to break new ground in the management of type …

28 years after the US first pioneered proton beam therapy at Loma Linda University Medical Center, the UK now has …

A surprise new name was thrown into the ring to take on Pfizer’s healthcare unit but speculation suggests that valuation …

After working to bring through Kite Pharma from the pre-clinical development stage to its final $12 billion acquisition by Gilead, …

NHS England is trialling centres that should be able to provide rapid answers as to whether a patient has cancer …

According to a piece by Bloomberg, Allergan is looking at options to divest its women’s health unit in a move …